These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21360486)

  • 41. No association between rheumatoid arthritis, amyotrophic lateral sclerosis, and tumour necrosis factor inhibitor treatment.
    Arkema EV; Feltelius N; Olsson T; Askling J;
    Ann Rheum Dis; 2014 Nov; 73(11):2061-2. PubMed ID: 25096786
    [No Abstract]   [Full Text] [Related]  

  • 42. Anti-tumor necrosis factor alpha therapy in rheumatoid arthritis: hitting two birds with one stone?
    Warrington KJ
    Arthritis Rheum; 2004 Jun; 51(3):309-10. PubMed ID: 15188311
    [No Abstract]   [Full Text] [Related]  

  • 43. Pharmacogenetics of methotrexate response in rheumatoid arthritis: an update.
    Ling SF; Bluett J
    Pharmacogenomics; 2020 Jan; 21(1):3-6. PubMed ID: 31849277
    [No Abstract]   [Full Text] [Related]  

  • 44. Monoamine oxidase inhibitors in rheumatoid arthritis-anti-tumor necrosis factor?
    Altschuler EL
    Int J Immunopharmacol; 2000 Nov; 22(11):1007-8. PubMed ID: 11203461
    [No Abstract]   [Full Text] [Related]  

  • 45. Tumor necrosis factor alpha haplotypes versus tumor necrosis factor alpha -308 G/A polymorphism in the prediction of infliximab treatment efficacy in rheumatoid arthritis.
    Mugnier B; Roudier J
    Arthritis Rheum; 2004 Dec; 50(12):4075-6; author reply 4076-7. PubMed ID: 15593229
    [No Abstract]   [Full Text] [Related]  

  • 46. Pathogenesis of arthritis: recent research progress.
    Feldmann M
    Nat Immunol; 2001 Sep; 2(9):771-3. PubMed ID: 11526382
    [No Abstract]   [Full Text] [Related]  

  • 47. Inhibitors of tumor necrosis factor in rheumatoid arthritis: Will that dog hunt?
    Kavanaugh A; Cohen S; Cush J
    J Rheumatol; 1998 Nov; 25(11):2049-53. PubMed ID: 9818641
    [No Abstract]   [Full Text] [Related]  

  • 48. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Systematic review of clinical trials on the treatment of rheumatoid arthritis with tumour necrosis factor alpha inhibitors].
    Reneses S; Pestana L
    Med Clin (Barc); 2001 May; 116(16):620-8. PubMed ID: 11412650
    [No Abstract]   [Full Text] [Related]  

  • 50. The evaluation of sleep quality and response to anti-tumor necrosis factor α therapy in rheumatoid arthritis patients.
    Karatas G; Bal A; Yuceege M; Yalcin E; Firat H; Dulgeroglu D; Karataş F; Sahin S; Cakci A; Ardic S
    Clin Rheumatol; 2017 Jan; 36(1):45-50. PubMed ID: 27567629
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular events in early rheumatoid arthritis--role of tumor necrosis factor inhibition.
    Ljung L
    J Rheumatol; 2014 Nov; 41(11):2094-6. PubMed ID: 25362704
    [No Abstract]   [Full Text] [Related]  

  • 52. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Okamoto H
    N Engl J Med; 2006 Nov; 355(19):2047; author reply 2048. PubMed ID: 17099950
    [No Abstract]   [Full Text] [Related]  

  • 53. Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: three centers experience.
    Salgado E; Campos J; Moreira-Navarrete V; Mulero J; Navarro F; Pérez-Pampín E; Carmona L; Gómez-Reino J
    Joint Bone Spine; 2013 Jul; 80(4):438-40. PubMed ID: 23453477
    [No Abstract]   [Full Text] [Related]  

  • 54. Rheumatoid arthritis.
    Klareskog L; Catrina AI; Paget S
    Lancet; 2009 Feb; 373(9664):659-72. PubMed ID: 19157532
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effectiveness and safety of the treatment with tumour necrosis factor alpha antagonists in rheumatoid arthritis patients].
    Arenere Mendoza M; Navarro Aznárez H; Rabanaque Hernández MJ; Manero Ruiz FJ
    Med Clin (Barc); 2005 Jun; 125(1):35-6. PubMed ID: 15960943
    [No Abstract]   [Full Text] [Related]  

  • 56. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.
    Redlich K; Schett G; Steiner G; Hayer S; Wagner EF; Smolen JS
    Arthritis Rheum; 2003 Dec; 48(12):3308-19. PubMed ID: 14673982
    [No Abstract]   [Full Text] [Related]  

  • 57. Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer.
    Symmons DP; Silman AJ
    Arthritis Rheum; 2004 Jun; 50(6):1703-6. PubMed ID: 15188344
    [No Abstract]   [Full Text] [Related]  

  • 58. Paradoxical psoriatic arthritis in a patient with rheumatoid arthritis treated by TNFα blocker.
    Villani AP; Weiler L; Jullien D; Chapurlat R; Confavreux C
    Joint Bone Spine; 2014 Oct; 81(5):455-6. PubMed ID: 24561024
    [No Abstract]   [Full Text] [Related]  

  • 59. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC
    Rheumatol Int; 2016 Jun; 36(6):837-44. PubMed ID: 27074847
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.
    Stokes MB; Foster K; Markowitz GS; Ebrahimi F; Hines W; Kaufman D; Moore B; Wolde D; D'Agati VD
    Nephrol Dial Transplant; 2005 Jul; 20(7):1400-6. PubMed ID: 15840673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.